» Articles » PMID: 39749111

Differences in Pulmonary Artery Flow Hemodynamics Between PAH and PH-HFpEF: Insights From 4D-Flow CMR

Overview
Journal Pulm Circ
Publisher Wiley
Specialty Pulmonary Medicine
Date 2025 Jan 3
PMID 39749111
Authors
Affiliations
Soon will be listed here.
Abstract

Pulmonary artery (PA) flow analysis is crucial for understanding the progression of pulmonary hypertension (PH). We hypothesized that PA flow characteristics vary according to PH etiology. In this study, we used 4D flow cardiovascular magnetic resonance imaging (CMR) to compare PA flow velocity and wall shear stress (WSS) between patients with pulmonary arterial hypertension (PAH) and those with heart failure with preserved ejection fraction and pulmonary hypertension (PH-HFpEF). We enrolled 13 PAH and 15 PH-HFpEF patients. All participants underwent echocardiography, 4D flow CMR, and right heart catheterization. We compared right ventricular outflow tract (RVOT) flow and main pulmonary artery (MPA) hemodynamics, including peak velocity and mean and maximum WSS, between groups. PH-HFpEF patients were older and more likely to have hypertension. PAH patients had higher mean PA pressure (47.8 ± 8.8 vs. 32.9 ± 6.9 mmHg,  < 0.001) and pulmonary vascular resistance (PVR) (8.6 ± 4.6 vs. 2.6 ± 2.2 wood unit,  < 0.001). RVOT systolic notching was more common in PAH patients (8 of 13 vs. 0 of 15), and they had shorter RVOT acceleration time (85.5 ± 20.9 vs. 135.0 ± 21.7 ms,  < 0.001). PAH patients had lower MPA Vmax (0.8 ± 0.2 vs. 1.1 ± 0.4 m/s,  = 0.032), mean WSS (0.29 ± 0.09 vs. 0.36 ± 0.06 Pa,  = 0.035), and maximal WSS (0.99 ± 0.18 vs. 1.21 ± 0.19 Pa,  = 0.011). Anterior MPA analysis confirmed lower WSS in PAH patients. PVR was negatively correlated with MPA mean WSS ( = -0.630,  = 0.002). PAH patients had lower MPA Vmax and lower mean MPA WSS in 4D flow CMR compared to PH-HFpEF patients. These distinct PA flow characteristics suggest that the flow hemodynamics of the PA remodeling process differ depending on the underlying etiology of PH.

Citing Articles

Advancing Cardiovascular Diagnostics: The Expanding Role of CMR in Heart Failure and Cardiomyopathies.

Parlati A, Nardi E, Marzano F, Madaudo C, Di Santo M, Cotticelli C J Clin Med. 2025; 14(3).

PMID: 39941536 PMC: 11818251. DOI: 10.3390/jcm14030865.


Adding a New Dimension to PH Imaging.

Bradley A, Gomberg-Maitland M Pulm Circ. 2025; 15(1):e70044.

PMID: 39867876 PMC: 11758092. DOI: 10.1002/pul2.70044.

References
1.
Kiely D, Levin D, Hassoun P, Ivy D, Jone P, Bwika J . EXPRESS: Statement on imaging and pulmonary hypertension from the Pulmonary Vascular Research Institute (PVRI). Pulm Circ. 2019; :2045894019841990. PMC: 6732869. DOI: 10.1177/2045894019841990. View

2.
Kovacs G, Bartolome S, Denton C, Gatzoulis M, Gu S, Khanna D . Definition, classification and diagnosis of pulmonary hypertension. Eur Respir J. 2024; 64(4). PMC: 11533989. DOI: 10.1183/13993003.01324-2024. View

3.
Gulan U, Rossi V, Gotschy A, Saguner A, Manka R, Brunckhorst C . A comparative study on the analysis of hemodynamics in the athlete's heart. Sci Rep. 2022; 12(1):16666. PMC: 9534940. DOI: 10.1038/s41598-022-20839-8. View

4.
Reiter G, Reiter U, Kovacs G, Kainz B, Schmidt K, Maier R . Magnetic resonance-derived 3-dimensional blood flow patterns in the main pulmonary artery as a marker of pulmonary hypertension and a measure of elevated mean pulmonary arterial pressure. Circ Cardiovasc Imaging. 2009; 1(1):23-30. DOI: 10.1161/CIRCIMAGING.108.780247. View

5.
Pieske B, Maggioni A, Lam C, Pieske-Kraigher E, Filippatos G, Butler J . Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study. Eur Heart J. 2017; 38(15):1119-1127. PMC: 5400074. DOI: 10.1093/eurheartj/ehw593. View